Compare Autodesk Inc (ADSK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Autodesk Inc vs BIO-TECHNE Corp — how do they compare? Autodesk Inc trades at $207.9 (market cap $44.84B), while BIO-TECHNE Corp trades at $70.93 (market cap $11.00B). The key difference: Autodesk Inc is far larger — about 4.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.
| ADSK | TECH | |
|---|---|---|
Market Cap | $44.84B | $11.00B |
Sector | Technology | Health |
52-Week High | $326.79 | $71.38 |
52-Week Low | $187.72 | $43.31 |
Enterprise Value | $44.64B | $11.08B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.
Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.
Bio-Techne (TECH) trades at $70.61, down 0.3% on the day, near its $73.00 takeover offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with strong moving averages, though RSI levels indicate overbought conditions. Fundamentals reveal a high P/E of 101.29 and declining net margins, but revenue remains stable near $1.22 billion. Cash flow improved in 2025 with $10.40M net inflow, and the balance sheet holds $152.86M cash against $319M long-term debt.
Outlook is dominated by the pending acquisition, offering a clear exit at $73.00, a 3.4% premium to current price. Risks include shareholder litigation questioning deal fairness and margin pressures. Analysts are unanimously positive with no sell ratings, seeing limited downside given the buyout bid. The stock presents a low-risk opportunity if the deal closes, but investors face uncertainty from legal challenges and earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autodesk Inc
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
